Quick Answer
Compass Therapeutics, Inc. reported R&D Expense of $14.90 million for fiscal year 2020.
Compass Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2020 | $14.90M | -33.6% |
| 2019 | $22.45M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2021 | $4.70M | +31.7% | +28.2% |
| September 30, 2020 | $3.67M | -38.6% | +22.9% |
| June 30, 2020 | $2.98M | -44.6% | -16.4% |
| March 31, 2020 | $3.57M | — | -40.3% |
| September 30, 2019 | $5.98M | — | +10.9% |
| June 30, 2019 | $5.39M | — | — |
- Compass Therapeutics, Inc. showed a decrease of -33.6% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2020 period, Compass Therapeutics, Inc.’s r&d expense has declined by 33.6% (from $22.45 million to $14.90 million).
- The most recent figure is from Compass Therapeutics, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 5, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: